

I-4
RECEIVED
FEB 1 2001
TECH CENTER 1600/2900

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW
1100 NEW YORK AVENUE, N.W., SUITE 600
WASHINGTON, D.C. 20005-3934

www.skf.com
PHONE: (202) 371-2600 FAXSIMILE: (202) 371-2540

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
ERIC K. STEFFE
MICHAEL O. LEE

STEVEN R. LUDWIG
JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.
DONALD R. MCPHAIL
PATRICK E. GARRETT
STEPHEN G. WHITESIDE
JEFFREY T. HELVEY*

HEIDI L. KRAUS
JEFFREY R. KURIN
RAYMOND MILLIEN
PATRICK D. O'BRIEN
LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES*
EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWITZ
PETER A. JACKMAN
MOLLY A. MCCALL
TERESA U. MEDLER

JEFFREY S. WEAVER
KRISTIN K. VIDOVICH
KENDRICK P. PATTERSON
DONALD J. FEATHERSTONE
GRANT E. REED
VINCENT L. CAPUANO
JOHN A. HARROUN*
MATTHEW M. CATLETT*
NATHAN K. KELLEY*
ALBERT J. FASULO II *
W. BRIAN EDGE*

KAREN R. MARKOWICZ**
SUZANNE E. ZISKA**
BRIAN J. DEL BUONO**
ANDREA J. KAMAGE**
NANCY J. LEITH**
TARJA H. NAUKKARINEN**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

November 1, 2000

WRITER'S DIRECT NUMBER:
(202) 371-2637
INTERNET ADDRESS:
KARENM@SKF.COM

Commissioner for Patents
Washington, D.C. 20231



Re: U.S. Utility Patent Application
Appl. No. 09/653,277; Filed: August 31, 2000
For: **Cell-Specific and/or Tumor Specific Promoter Retargeting of Herpes
Gamma 34.5 Gene Expression**
Inventors: Chiocca and Chung
Our Ref: 0609.4880002/JAG/KRM

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement (*in duplicate*);
2. List of documents cited on Form PTO-1449 (38 sheets);
3. Copies of the documents listed on Form PTO-1449 (121 documents); and
4. One (1) return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
November 1, 2000
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz
Agent for Applicants
Registration No. 36,351

JAG/KRM/awt
Enclosures

P:\USERS\ATERRY\0609\488-2\pto cover letter ids
SKGF Rev. 4/27/00 mac

RECEIVED
FEB 1 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Chiocca and Chung

Appl. No. 09/653,277

Filed: August 31, 2000

For: **Cell-Specific and/or Tumor-Specific Promoter Retargeting of Herpes Gamma 34.5 Gene Expression**



Art Unit: To Be Assigned

Examiner: To Be Assigned

Atty. Docket: 0609.4880002/JAG/KRM

+3
3-12-01
P.Z

Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of these documents is provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not

exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Regarding Document AT7, an internet version of this publication was apparently released a short time prior to September 1999.


This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz
Agent for Applicants
Registration No. 36,351

Date: 11/11/00

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.488002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	PATENT NOV 01 2000 669 RECEIVED TECH CENTER 1600/2000
		FILING DATE August 31, 2000	
		GROUP To Be Assigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA1	5,288,641	02/22/1994	Roizman	435	320.1	07/30/1992
AB1	5,585,096	12/17/1996	Martuza et al.	424	93.2	06/23/1994
AC1	5,688,773	11/18/1997	Chiocca et al.	514	RECEIVED	10/28/1994
AD						
AE					FER 1	
AF					2001	
AG					TECH CENTER 1600/2000	
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL1	WO 96/00007	01/04/1996	WIPO			Yes No
AM1	WO 96/03997	02/15/1996	WIPO			Yes No
AN1	WO 97/04804	02/13/1997	WIPO			Yes No
AO1	WO 98/42195	10/01/1998	WIPO			Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	1	Abe, M. and Kufe, D., "Characterization of Cis-Acting Elements Regulating Transcription of the Human DF3 Breast Carcinoma-Associated Antigen (MUC1) Gene," Proc. Natl. Acad. Sci. USA 90:282-286 (1993).
AS	1	Albarracin, C.T., et al., "The Gonadotropin-Releasing Hormone Receptor Gene Promoter Directs Pituitary-Specific Oncogene Expression in Transgenic Mice," Endocrinology 140:2415-2421 (May 1999).
AT	1	Amizuka, N., et al., "Vitamin D3 Differentially Regulates Parathyroid Hormone/Parathyroid Hormone-Related Peptide Receptor Expression in Bone and Cartilage," J. Clin. Invest. 103:373-381 (February 1999).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	GROUP To Be Assigned
		FILING DATE August 31, 2000	

Page 2 of 38
RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
NOV 01 2000

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA					FEB 1 2001		
AB					TECH CENTER 1600/2900		
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	2	Andreansky, S.S., et al., "The Application of Genetically Engineered Herpes Simplex Viruses to the Treatment of Experimental Brain Tumors," Proc. Natl. Acad. Sci. USA 93:11313-11318 (1996).
AS	2	Arbuthnot, P., et al., "Hepatoma Cell-Specific Expression of a Retrovirally Transferred Gene is Achieved by Alpha-Fetoprotein but not Insulinlike Growth Factor II Regulatory Sequences," Hepatology 22:1788-1796 (1995).
AT	2	Bennett, J.D., et al., "E2F Binding is Required but Not Sufficient for Repression of B-myb Transcription in Quiescent Fibroblasts," Oncogene 13:1073-1082 (1996).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	NOV 01 2000 U.S. PATENT & TRADEMARK OFFICE
		FILING DATE August 31, 2000	
U.S. PATENT DOCUMENTS			

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	3	Bischoff, J.R., et al., "An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells," <i>Science</i> 274:373-376 (1996).
AS	3	Boviatsis, E.J., et al., "Long-Term Survival of Rats Harboring Brain Neoplasms Treated with Ganciclovir and a Herpes Simplex Virus Vector that Retains an Intact Thymidine Kinase Gene," <i>Cancer Res.</i> 54:5745-5751 (1994).
AT	3	Boviatsis, E.J., et al., "Antitumor Activity and Reporter Gene Transfer into Rat Brain Neoplasms Inoculated with Herpes Simplex Virus Vectors Defective in Thymidine Kinase or Ribonucleotide Reductase," <i>Gene Ther.</i> 1:323-331 (1994).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	NOV 01 2000
		FILING DATE August 31, 2000	GROUP To Be Assigned

PATENT TRADEMARK
EXAMINER'S
RECEIPT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	4	Burns, J.C., et al., "Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells," Proc. Natl. Acad. Sci. USA 90:8033-8037 (1993).
AS	4	Caruso, M., et al., "Regression of established macroscopic liver metastases after in situ trasnduction of a suicide gene," Proc. Natl. Acad. Sci. USA 90:7024-7028 (1993).
AT	4	Chambers, R., et al., "Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma," Proc. Natl. Acad. Sci. USA 92: 1411-1415 (1995).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	NOV 01 2000 JCS
		FILING DATE August 31, 2000	GROUP To Be Assigned
		PATENT	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	5	Chase, M., et al., "An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy," <i>Nature Biotechnol.</i> 16:444-448 (1998).
	AS	5	Chen, S.H., et al., "Gene Therapy for Brain Tumors: Regression of Experimental Gliomas by Adenovirus-Mediated Gene Transfer In Vivo," <i>Proc. Natl. Acad. Sci. USA</i> 91:3054-3057 (1994).
	AT	5	Chen, L., et al., "Breast Cancer Selective Gene Expression and Therapy Mediated by Recombinant Adenoviruses Containing the DF3/MUC1 Promoter," <i>J. Clin. Invest.</i> 96:2775-2782 (1995).

EXAMINER	/	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	
		FILING DATE August 31, 2000	GROUP To Be Assigned



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	TRANSLATION
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						



FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	6	Chen, L., and Waxman, D.J., "Intratumoral Activation and Enhanced Chemotherapeutic Effect of Oxazaphosphorines following Cytochrome P-450 Gene Transfer: Development of a Combined Chemotherapy/Cancer Gene Therapy Strategy," <i>Cancer Res.</i> 55:581-589 (1995).
AS	6	Chen, L., et al., "Sensitization of Human Breast Cancer Cells to Cyclophosphamide and Ifosfamide by Transfer of a Liver Cytochrome P450 Gene," <i>Cancer Res.</i> 56:1331-1340 (1996).
AT	6	Chou, J. and Roizman, B., "The $\gamma_1(34.5)$ Gene of Herpes Simplex Virus 1 Precludes Neuroblastoma Cells from Triggering Total Shutoff of Protein Synthesis Characteristic of Programed Cell Death in Neuronal Cells," <i>Proc. Natl. Acad. Sci. USA</i> 89:3266-3270 (1992).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
			APPLICANT Chiocca and Chung	  	
			FILING DATE August 31, 2000		
GROUP To Be Assigned					

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						




FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	Z	Chou, J., et al., "Association of a M, 90,000 Phosphoprotein with Protein Kinase PKR in Cells Exhibiting Enhanced Phosphorylation of Translation Initiation Factor eIF-2 Alpha and Premature Shutoff of Protein Synthesis After Infection with Gamma 134.5- Mutants of Herpes Simplex Virus 1," Proc. Natl. Acad. Sci. USA 92:10516-10520 (1995).
AS	Z	Chung, R.Y. and Chiocca, E.A., "Gene Therapy for Tumors of the Central Nervous System," Surg. Oncol. Clin. N. Am. 7:589-602 (1998).
AT	Z	Chung, R.Y., et al., "B-myb Promoter Retargeting of Herpes Simplex Virus γ34.5 Gene-Mediated Virulence Toward Tumor and Cycling Cells," J. Virol. 73:7556-7564 (September 1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung	  	
		FILING DATE August 31, 2000		
		GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	8	Clary, B.M., et al., "Transcriptional Targeting for Cancer Gene Therapy," <i>Surg. Oncol. Clin. N. Am.</i> 7:565-574 (1998).
	AS	8	Coffey, M.C., et al., "Reovirus Therapy of Tumors with Activated Ras Pathway," <i>Science</i> 282:1332-1334 (1998).
	AT	8	Coll-Fresno, P.M., et al., "Cytotoxic Activity of a Diphteria Toxin/FGF6 Mitotoxin on Human Tumour Cell Lines," <i>Oncogène</i> 14:243-247 (1997).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung	NOV 01 2000 PATENT & TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE	
		FILING DATE August 31, 2000		
		GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	9	Colombo, M.P., et al., "Immunotherapy. I: Cytokine Gene Transfer Strategies," <i>Cancer Metastasis Rev.</i> 16:421-432 (1997).
	AS	9	Connors, T.A., "The Choice of Prodrugs for Gene Directed Enzyme Prodrug Therapy of Cancer," <i>Gene Ther.</i> 2:702-709 (1995).
	AT	9	Culver, K.W., "Clinical applications of gene therapy for cancer," <i>Clin. Chem.</i> 40:510-512 (1994).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609-4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	PATENT NO. 6,600,000 NOV 01 2000 U.S. PATENT DOCUMENTS
		FILING DATE August 31, 2000	
GROUP To Be Assigned			

Page 10 of 38

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>10</u>	Dachs, G.U., et al., "Targeting Gene Therapy to Cancer: A Review," <i>Oncol. Res.</i> 9:313-325 (1997).
AS	<u>10</u>	Dehal, S.S., et al., "CYP2D6 Catalyzes Tamoxifen 4-hydroxylation in Human Liver," <i>Cancer Res.</i> 57:3402-3406 (1997).
AT	<u>10</u>	Deonarain, M.P., et al., "Genetic Delivery of Enzymes for Cancer Therapy," <i>Gene Therapy</i> 2: 235-244 (1995).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung	 NOV 07 2000	
		FILING DATE August 31, 2000		
		GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>11</u>	Ezzeddine, Z.D., et al., "Selective Killing of Glioma Cells in Culture and <i>in Vivo</i> by Retrovirus Transfer of the Herpes Simplex Virus Thymidine Kinase gene," <i>New Biol.</i> 3:608-614 (1991).
AS	<u>11</u>	Fakhrai, H., et al., "Eradication of Established Intracranial Rat Gliomas by Transforming Growth Factor β Antisense Gene Therapy," <i>Proc. Natl. Acad. Sci. USA</i> 93:2909-2914 (1996).
AT	<u>11</u>	Freeman, S.M., et al., "In Situ Use of Suicide Genes for Cancer Therapy," <i>Semin. Oncol.</i> 23:31-45 (1996).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung		
		FILING DATE August 31, 2000		
		GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>12</u>	Freytag, S.O., et al., "A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Gene, and Radiotherapy," <i>Hum. Gene Ther.</i> 9:1323-1333 (1998).
	AS	<u>12</u>	Friedlos, F. et al., "Mustard Prodrugs for Activation by <i>Escherichia coli</i> Nitroreductase in Gene-Directed Enzyme Prodrug Therapy," <i>J Med Chem</i> 40:1270-1275 (1997).
*	AT	<u>12</u>	Gage, P.J., et al., "A Cell-Free Recombination System for Site-Specific Integration of Multigenic Shuttle Plasmids Into the Herpes Simplex Virus Type 1 Genome," <i>J. Virol.</i> 66:5509-5515 (1992).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	
		FILING DATE August 31, 2000	GROUP To Be Assigned



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>13</u>	Gale, M., et al., "Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation," <i>Mol. Cell. Biol.</i> 18:5208-5218 (1998).
	AS	<u>13</u>	Glorioso, J.C., et al., "Herpes simplex virus-based vectors," <i>Seminars in Virology</i> 3:265-276 (1992).
	AT	<u>13</u>	Glorioso, J.C., et al., "Development and Application of Herpes Simplex Virus Vectors for Human Gene Therapy," <i>Annu. Rev. Microbiol.</i> 49:675-710 (1995).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	GROUP To Be Assigned
		FILING DATE August 31, 2000	


 NOV 07 2000

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	14	Goeptar, A.R., et al., "Cytotoxicity of Mitomycin C and Adriamycin in Freshly Isolated Rat Hepatocytes: The Role of Cytochrome P450," <i>Cancer Res.</i> 54:2411-2418 (1994).
AS	14	Goldstein, D.J. and Weller, S.K., "Herpes Simplex Virus Type 1-Induced Ribonucleotide Reductase Activity is Dispensable for Virus Growth and DNA Synthesis: Isolation and Characterization of an ICP6 lacZ Insertion Mutant," <i>J. Virol.</i> 62:196-205 (1988).
AT	14	Goldstein, D.J. and Weller, S.K., "An ICP6::lacZ Insertional Mutagen is Used to Demonstrate That the UL52 Gene of Herpes Simplex Virus Type 1 is Required for Virus Growth and DNA Synthesis," <i>J. Virol.</i> 62:2970-2977 (1988).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung		
		FILING DATE August 31, 2000		
		GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	15	Guillot, P.V., et al., "A Vascular Bed-Specific Pathway Regulates Cardiac Expression of Endothelial Nitric Oxide Synthase," <i>J. Clin. Invest.</i> 103:799-805 (March 1999).
	AS	15	Hallenbeck, P.L., et al., "A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma," <i>Hum. Gene Ther.</i> 10:1721-1733 (July 1999).
	AT	15	Hart, I.R., et al., "Targeted Therapy for Malignant Melanoma," <i>Curr. Opin. Oncol.</i> 6:221-225 (1994).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	GROUP To Be Assigned
		FILING DATE August 31, 2000	

O I P E
Nov 01 2000
RECEIVED
U.S. PATENT AND TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS



EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>16</u>	Hart, I.R., "Tissue Specific Promoters in Targeting Systemically Delivered Gene Therapy," <i>Semin. Oncol.</i> 23:154-158 (1996).
AS	<u>16</u>	He, B., et al., "The γ 134.5 Protein of Herpes Simplex Virus 1 Has the Structural and Functional Attributes of a Protein Phosphatase 1 Regulatory Subunit and is Present in a High Molecular Weight Complex with the Enzyme in Infected Cells," <i>J. Biol. Chem.</i> 273:20737-20743 (1998).
AT	<u>16</u>	Hollywood, D., and Hurst, H., "A Novel Transcription Factor, OB2-1, is Required for Overexpression of the Proto-Oncogene c-erbB-2 in Mammary Tumour Lines," <i>EMBO J</i> 12:2369-2375 (1993).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung	  	
		FILING DATE August 31, 2000		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	17	Hunter, W.D., et al., "Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation of Intracerebral Injection in Nonhuman Primates," <i>J. Virol.</i> 73:6319-6326 (August 1999).
	AS	17	Hwang, J.J., et al., "Novel Retroviral Vector Transferring a Suicide Gene and a Selectable Marker Gene With Enhanced Gene Expression by Using a Tetracycline-Responsive Expression System," <i>J. Virol.</i> 70:8138-8141 (1996).
	AT	17	Ikeda, K., et al., "Oncolytic Virus Therapy of Multiple Tumors in the Brain Requires Suppression of Innate and Elicited Antiviral Responses," <i>Nat. Med.</i> 5:881-887 (1999).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung	 NOV 01 2000 U.S. PATENT AND TRADEMARK OFFICE	
		FILING DATE August 31, 2000		
		GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>18</u>	Jain, R.K., "Delivery of Molecular Medicine to Solid Tumors," <i>Science</i> 271:1079-1080 (1996).
	AS	<u>18</u>	Jérôme, V., and Müller, R., "Tissue-Specific, Cell Cycle-Regulated Chimeric Transcription Factors for the Targeting of Gene Expression to Tumor Cells," <i>Hum. Gene Ther.</i> 9:2653-2659 (1998).
	AT	<u>18</u>	Johnson, P.A., et al., "Cytotoxicity of a Replication-Defective Mutant of Herpes Simplex Virus Type 1," <i>J. Virol.</i> 66:2952-2965 (1992).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	GROUP To Be Assigned
		FILING DATE August 31, 2000	

O P E
NOV 01 2000
PATENT & TRADEMARK OFFICE
U.S. GOVERNMENT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>19</u>	Kappel, A., et al., "Identification of Vascular Endothelial Growth Factor (VEGF) Receptor-2 (Flk-1) Promoter/Enhancer Sequences Sufficient for Angioblast and Endothelial Cell-Specific Transcription in Transgenic Mice," <i>Blood</i> 93:4284-4292 (June 1999).
AS	<u>19</u>	Kesari, S., et al., "Therapy of Experimental Human Brain Tumors Using a Neuroattenuated Herpes Simplex Virus Mutant," <i>Lab. Invest.</i> 73:636-648 (1995).
AT	<u>19</u>	Kooby, D.A., et al., "Oncolytic Viral Therapy for Human Colorectal Cancer and Liver Metastases Using a Multi-Mutated Herpes Simplex Virus Type-1 (G207)," <i>FASEB J.</i> 13:1325-1334 (August 1999).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung		
		FILING DATE August 31, 2000		
		GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>20</u>	Kramm, C.M., et al., "Therapeutic Efficiency and Safety of a Second-Generation Replication-Conditional HSV1 Vector for Brain Tumor Gene Therapy," <i>Hum. Gene Ther.</i> 8:2057-2068 (1997).
	AS	<u>20</u>	Lam, E.W., et al., "Cell-cycle regulation of human B-myb transcription," <i>Gene</i> 160:277-281 (1995).
	AT	<u>20</u>	Lan, K-H., et al., "In Vivo Selective Gene Expression and Therapy Mediated by Adenoviral Vectors for Human Carcinoembryonic Antigen-producing Gastric Carcinoma," <i>Cancer Res.</i> 57:4279-4284 (1997).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	GROUP To Be Assigned
		FILING DATE August 31, 2000	



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>21</u>	LeBlanc, G.A. and Waxman, D.J., "Interaction of Anticancer Drugs with Hepatic Monooxygenase Enzymes," <i>Drug Metab. Rev.</i> 20:395-439 (1989).
AS	<u>21</u>	Lorenz, R.M. et al., "Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus Therapy," <i>J. Natl. Cancer. Inst.</i> 86:1228-1233 (1994).
AT	<u>21</u>	Lukas, J., et al., "Deregulated Expression of E2F Family Members Induces S-phase Entry and Overcomes p16INK4A-Mediated Growth Suppression," <i>Mol. Cell. Biol.</i> 16:1047-1057 (1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	PATENTED NOV 01 2000 REMAILED JCS
		FILING DATE August 31, 2000	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>22</u>	Lundwall, A., "Characterization of the Gene for Prostate-Specific Antigen, a Human Glandular Kallikrein," <i>Biochem. Biophys. Res. Commun.</i> 161:1151-1156 (1989).
	AS	<u>22</u>	Lyon, J., et al., "The Role of Myb Proteins in Normal and Neoplastic Cell Proliferation," <i>Crit. Rev. Oncogenesis</i> 5:373-388 (1994).
	AT	<u>22</u>	Manome, Y., et al., "Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide," <i>Gene Therapy</i> 3:513-520 (1996).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	FILING DATE August 31, 2000
		GROUP To Be Assigned	 NOV 07 2000

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>23</u>	Markert, J.M., et al. "Expanded Spectrum of Viral Therapy in the Treatment of Nervous System Tumors," <i>Neurosurg.</i> 77:590-594 (1992).
AS	<u>23</u>	Martuza, R.L., et al., "Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant," <i>Science</i> 252:854-856 (1991).
AT	<u>23</u>	Martuza, R.L., "Conditionally Replicating Herpes Vectors For Cancer Therapy," <i>J. Clin. Invest.</i> 105:841-846 (April 2000).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	FILING DATE August 31, 2000

O I P E
NOV 8 1 2000
JC 69
P A T E N T
U. S. P A T E N T O F F I C E

U. S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
-	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						



FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>24</u>	Massie, B., et al., "Inducible Overexpression of a Toxic Protein by an Adenovirus Vector with a Tetracycline-Regulatable Expression Cassette," <i>J. Virol.</i> 72:2289-2296 (1998).
AS	<u>24</u>	McLauchlan, J., and Clements, J.B., "Organization of the Herpes Simplex Virus Type 1 Transcription Unit Encoding Two Early Proteins with Molecular Weights of 140000 and 40000," <i>J. Gen. Virol.</i> 64:997-1006 (1983).
AT	<u>24</u>	Miller, N., and Vile, R., "Targeted vectors for gene therapy," <i>FASEB J.</i> 9:190-199 (1995).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung	 NOV 01 2000 	
		FILING DATE August 31, 2000		
		GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>25</u>	Miller, N. and Whelan, J., "Progress in Transcriptionally Targeted and Regulatable Vectors for Genetic Therapy," <i>Hum. Gene Ther.</i> 8:803-815 (1997).
AS	<u>25</u>	Mineta, T., et al., "Treatment of Malignant Gliomas Using Ganciclovir-Hypersensitive, Ribonucleotide Reductase-Deficient Herpes Simplex Viral Mutant," <i>Cancer Res.</i> 54:3963-3966 (1994).
AT	<u>25</u>	Mineta, T., et al., "Attenuated Multi-Mutated Herpes Simplex Virus-1 for the Treatment of Malignant Gliomas," <i>Nature Med.</i> 1:938-943 (1995).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	PATENT NUMBER NOV 01 2000 JCS9
		FILING DATE August 31, 2000	
		GROUP To Be Assigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>26</u>	Miyatake, S., et al., "Transcriptional Targeting of Herpes Simplex Virus for Cell-Specific Replication," <i>J. Virol.</i> 71:5124-5132 (1997).
	AS	<u>26</u>	Mohr, I. and Bluzman, Y., "A Herpesvirus Genetic Element Which Affects Translation in the Absence of the Viral GADD34 Function," <i>EMBO J.</i> 15:4759-4766 (1996).
	AT	<u>26</u>	Moolten, F.L. and Wells, J.M., "Curability of Tumors Bearing Herpes Thymidine Kinase Genes Transferred by Retroviral Vectors," <i>J. Natl. Cancer Inst.</i> 82:297-300 (1990).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	PATENT NUMBER NOV 01 2000 CS9 RE-DEMAILED 11/01/2000
		FILING DATE August 31, 2000	
		GROUP To Be Assigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>27</u>	Moolten, F.L., "Drug sensitivity ("suicide") genes for selective cancer chemotherapy," <i>Cancer Gene Ther.</i> 1:279-287 (1994).
	AS	<u>27</u>	Mullen, C.A., et al., "Tumors Expressing the Cytosine Deaminase Suicide Gene Can Be Eliminated in Vivo with 5-Fluorocytosine and induce protective immunity to Wild Type Tumor," <i>Cancer Res.</i> 54:1503-1506 (1994).
	AT	<u>27</u>	Nagayama, Y., et al., "Enhanced Efficacy of Transcriptionally Targeted Suicide Gene/Prodrug Therapy for Thyroid Carcinoma with the Cre-loxP System," <i>Cancer Res.</i> 59:3049-3052 (July 1999).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung	 NOV 01 2000 689	
		FILING DATE August 31, 2000		
		GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	TRANSLATION	FILING DATE
	AA							
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							
	AH							
	AI							
	AJ							
	AK							

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>28</u>	Ng, S.F. and Waxman D.J., "Activation of thio-TEPA cytotoxicity toward human breast cancer cells by hepatic cytochrome P450," <i>Int'l. J. Oncology</i> 2:731-738 (1993).
AS	<u>28</u>	Nilaver, G., et al., "Delivery of Herpesvirus and Adenovirus to Nude Rat Intracerebral Tumors After Osmotic Blood-Brain Barrier Disruption," <i>Proc. Natl. Acad. Sci. USA</i> 92: 9829-9833 (1995).
AT	<u>28</u>	O'Malley, B.W., Jr., et al., "Combination Gene Therapy for Oral Cancer in a Murine Model," <i>Cancer Res.</i> 56:1737-1741 (1996).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. OIPE 09/653,277
		APPLICANT Chiocca and Chung	
		FILING DATE August 31, 2000	
		GROUP To Be Assigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>29</u>	Oldfield, E., et al., "Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction with the Thymidine Kinase Gene and Intravenous Ganciclovir," <i>Hum. Gene Ther.</i> 4:39-69 (1993).
AS	<u>29</u>	Osaki, T., et al., "Gene Therapy for Carcinoembryonic Antigen-Producing Human Lung Cancer Cells by Cell Type-Specific Expression of Herpes Simplex Virus Thymidine Kinase Gene," <i>Cancer Res.</i> 54:5258-5261 (1994).
AT	<u>29</u>	Perng, G.-C., et al., "An Avirulent ICP34.5 Deletion Mutant of Herpes Simplex Virus Type 1 Is Capable of In Vivo Spontaneous Reactivation," <i>J. Virol.</i> 69:3033-3041 (1995).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung	NOV 01 2000 U.S. PATENT & TRADEMARK OFFICE	
		FILING DATE August 31, 2000	GROUP To Be Assigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>30</u>	Pyles, R.B. and Thompson, R.I., "Evidence That the Herpes Simplex Virus Type 1 Uracil DNA Glycosylase is Required for Efficient Viral Replication and Latency in the Murine Nervous System," <i>J. Virol.</i> 68:4963-4972 (1994).
AS	<u>30</u>	Pyles, R.B., et al., "A Novel Multiply-Mutated HSV-1 Strain for the Treatment of Human Brain Tumors," <i>Hum. Gene Ther.</i> 8:533-544 (1997).
AT	<u>30</u>	Rainov, N.G., et al., "Retrovirus-Mediated Gene Therapy of Experimental Brain Neoplasms Using the Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Paradigm," <i>Cancer Gene Therapy</i> 3:99-106 (1996).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung		
		FILING DATE August 31, 2000		
		GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>31</u>	Rainov, N.G., et al., "New Prodrug Activation Gene Therapy for Cancer Using Cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol," <i>Hum. Gene Ther.</i> 9:1261-1273 (1998).
AS	<u>31</u>	Ram, Z., et al., "Therapy of Malignant Brain Tumors by Intratumoral Implantation of Retroviral Vector-Producing Cells," <i>Nature Medicine</i> 3:1354-1361 (1997).
AT	<u>31</u>	Ray, M.K., et al., "β Cell-Specific Ablation of Target Gene Using Cre-loxP System in Transgenic Mice," <i>J. Surg. Res.</i> 84:199-203 (June 1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung	  NOV 01 2000	
		FILING DATE August 31, 2000		
		GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>32</u>	Rodriguez, R., et al., "Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-Specific Antigen-Positive Prostate Cancer Cells," <i>Cancer Res.</i> 57:2559-2563 (1997).
	AS	<u>32</u>	Roizman, B. and Jenkins, F.J., "Genetic Engineering of Novel Genomes of Large DNA Viruses," <i>Science</i> 229:1208-1214 (1985).
	AT	<u>32</u>	Rosenberg, S.A., et al., "Human Gene Marker/Therapy Clinical Protocols," <i>Hum. Gene Ther.</i> 11:919-979 (April 2000).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung	 <div style="display: flex; align-items: center; justify-content: space-between;"> NOV 11 2000 GROUP To Be Assigned </div>	
		FILING DATE August 31, 2000		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>33</u>	Roth, J.A., et al., "Retrovirus-Mediated Wild-Type p53 Gene Transfer to Tumors of Patients with Lung Cancer," <i>Nature Med.</i> 2:985-991 (1996).
	AS	<u>33</u>	Roth, J.A. and Cristiano, R.J., "Gene Therapy for Cancer: What Have We Done and Where are We Going?" <i>J. Natl. Cancer Inst.</i> 89:21-39 (1997).
	AT	<u>33</u>	Schnierle, B.S. and Groner, B., "Retroviral Targeted Delivery," <i>Gene Therapy</i> 3:1069-1073 (1996).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung		
		FILING DATE August 31, 2000		
		GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>34</u>	Spear, M.A., et al., "Targeting gene therapy vectors to CNS malignancies," <i>J. NeuroViro1.</i> 4:133-147 (1998).
AS	<u>34</u>	Spear, M.A., "Gene Therapy of Gliomas: Receptor and transcriptional Targeting," <i>Anticancer Research</i> 18:3223-3232(1998).
AT	<u>34</u>	Toda, M., et al., "In Situ Cancer Vaccination: An IL-12 Defective Vector/Replication-Competent Herpes Simplex Virus Combination Induces Local and Systemic Antitumor Activity," <i>J. Immunol.</i> 160:4457-4464 (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung		
		FILING DATE August 31, 2000	GROUP To Be Assigned	

O I P E
NOV 01 2000
U.S. PATENT AND TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>35</u>	Toda, M., et al., "Herpes Simplex Virus as an In Situ Cancer Vaccine for the Induction of Specific Anti-Tumor Immunity," <i>Hum. Gene. Ther.</i> 10:385-393 (February 1999).
AS	<u>35</u>	Ueki, K., et al., "CDKN2/p16 or RB Alterations Occur in the Majority of Glioblastomas and Are Inversely Correlated," <i>Cancer Res.</i> 56:150-153 (1996).
AT	<u>35</u>	Vite, R.G. and Hart, T.R., "In Vitro and in Vivo Targeting of Gene Expression to Melanoma Cells," <i>Cancer Res.</i> 53:962-967 (1993).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung	 NOV 01 2000 JC PTO-1449 653	
		FILING DATE August 31, 2000		
		GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>36</u>	Vile, R.G., "Tumor-specific gene expression," <i>Semin. Cancer Biol.</i> 5:429-436 (1994).
	AS	<u>36</u>	Walther, W., and Stein, U., "Targeted Vectors for Gene Therapy of Cancer and Retroviral Infections," <i>Mol. Biotechnol.</i> 6:267-286 (1996).
	AT	<u>36</u>	Walther, W. and Stein, U., "Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting," <i>J. Mol. Med.</i> 74:379-392 (1996).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277	
		APPLICANT Chiocca and Chung		
		FILING DATE August 31, 2000		
		GROUP To Be Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>37</u>	Wei, M.X., et al., "Experimental Tumor Therapy in mice Using the Cyclophosphamide-Activating Cytochrome P450 2B1 Gene," <i>Hum. Gene Ther.</i> 5:969-978 (1994).
AS	<u>37</u>	Yang, C., et al., "Paired-Like Homeodomain Proteins, Phox2a and Phox2b, are Responsible for Noradrenergic Cell-Specific Transcription of the Dopamine β -hydroxylase Gene," <i>J. Neurochem.</i> 71: 1813-1826 (1998).
AT	<u>37</u>	Nakamura, H., et al., "Oncolysis of Colon Carcinoma Liver Metastasis in Genetically Engineered HSV-1 Vector MTB34.5," <i>Proc. Am. Assoc. Cancer Res. Ann. Meet.</i> 41:466 Abstract No. 2970 (March 2000).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0609.4880002	APPLICATION NO. 09/653,277
		APPLICANT Chiocca and Chung	
		FILING DATE August 31, 2000	GROUP To Be Assigned



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>38</u>	Yoon, S.S. and Tanabe, K.K., "Surgical Treatment and Other Regional Treatments for Colorectal Cancer Liver Metastases," <i>Oncologist</i> . 4:197-208 (1999).
AS	<u>38</u>	Yoon, S.S., et al., "An Oncolytic Herpes Simplex Virus Type 1 Selectively Destroys Diffuse Liver Metastases from Colon Carcinoma," <i>FASEB J.</i> 14:301-311 (February 2000).
AT	<u>38</u>	Munaut, C., et al., "Murine Matrix Metalloproteinase 9 Gene," <i>J. Biol. Chem.</i> 274:5588-5596 (1999).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.